ARS Pharmaceuticals (NASDAQ:SPRY) Stock

ARS PHARMACEUTICALS INC

ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

ARS Pharmaceuticals Inc

Antalpha Platform Holding Company ("Antalpha" or the "Company") today announced the pricing of its initial public offering of 3,850,000 ordinary shares at a price to the public of $12.80 per ordinary share. The ordinary shares have been approved for listing and are expected to begin trading on the Nasdaq Global Market on May 14, 2025, under the ticker symbol "ANTA." The offering is expected to close on May 15, 2025, subject to customary closing conditions.
Antalpha has granted the underwriters a 30-day option to purchase an additional 577,500 ordinary shares to cover over-allotments in connection with the offering.

News

IPOs

ANTA

Antalpha Announces Pricing Of Initial Public Offering Of 3.85M Shares At A Price Of $12.80 Per Share

Citigroup analyst Arthur Truslove downgrades UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) from Buy to Neutral and raises the price target from $60.5 to $71.

Downgrades

Price Target

Analyst Ratings

Citigroup Downgrades UL Solutions to Neutral, Raises Price Target to $71

IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.38) by 10.53 percent. This is a 13.33 percent decrease over losses of $(0.30) per share from the same period last year.

Earnings

Earnings Beats

IOBT

IO Biotech Q1 EPS $(0.34) Beats $(0.38) Estimate

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the communication services sector.
<h3 class="wp-block-heading">Shutterstock, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.83%</li>
<li>JMP Securities analyst Andrew Boone reiterated a Market Perform rating on May 5, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Needham analyst Bernie McTernan maintained a Buy rating and cut the price target from $45 to $30 on March 7, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 2, the company posted downbeat quarterly results</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">SSTK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="896" height="811" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png" alt="" class="wp-image-914631" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044751/image-156-768x695.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 6.35%</li>
<li>Tigress Financial analyst Ivan Feinseth maintained a Buy rating and raised the price target from $55 to $56 on April 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Scotiabank analyst Maher Yaghi maintained a Sector Perform rating and increased the price target from $48.5 to $49 on April 23, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On May 13, Verizon announced a $5 billion commitment to continue investing in America and supporting small businesses.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">latest VZ news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="907" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png" alt="" class="wp-image-914632" style="width:698px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044824/image-157-768x709.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Nexstar Media Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>)</h3>
<ul class="wp-block-list">
<li>Dividend Yield: 4.27%</li>
<li>Benchmark analyst Daniel Kurnos maintained a Buy rating and raised the price target from $215 to $220 on May 9, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Wells Fargo analyst Steven Cahall maintained an Overweight rating and cut the price target from $216 to $200 on May 1, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On May 8, Nexstar Media Group reported better-than-expected first-quarter EPS results.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest NXST <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="895" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png" alt="" class="wp-image-914635" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158.png 895w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14044903/image-158-768x709.png 768w" sizes="(max-width: 895px) 100vw, 895px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Markets

Trading Ideas

NXST

SSTK

Wall Street's Most Accurate Analysts Spotlight On 3 Tech And Telecom Stocks Delivering High-Dividend Yields

Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) affirms FY2025 sales outlook from $30.00 million to $30.00 million vs $40.20 million estimate.

Guidance

ALUR

Allurion Technologies Affirms FY2025 Sales Guidance of $30.00M vs $40.20M Est

WIIM

IXHL

Incannex Healthcare shares are trading higher after the company completed patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study of IHL-42X for obstructive sleep apnea.

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.66) per share. This is a 1.49 percent increase over losses of $(0.67) per share from the same period last year. The company reported $162.46 thousand in sales this quarter. This is a 57.31 percent decrease over sales of $380.57 thousand the same period last year.

APRE

Aprea Therapeutics Q1 EPS $(0.66) Up From $(0.67) YoY, Sales $162.46K Down From $380.57K YoY

Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.35) by 31.43 percent. This is a 85.37 percent increase over losses of $(1.64) per share from the same period last year.

BNTC

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.35) Estimate

Kalaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLRS#NASDAQ">KLRS</a>) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.17) by 115.38 percent. This is a 3.08 percent increase over losses of $(2.60) per share from the same period last year.

Earnings Misses

KLRS

Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate

<a href="https://www.globenewswire.com/Tracker?data=VFi76zOPFziMSR2L83lWTcD9X8IU9_hdqO5B40n9RLxP2qqmSR1JF-raa6_Ik_4j4qJiYG-antKeH0DlGMEp7fyTIIWVfSorVwAMNQP3aCc=">Enphase Energy, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that homeowners in all of New York's major investor-owned electric utility service territories who install Enphase IQ&#xAE; Batteries can now qualify to enroll in the NYSERDA New York Battery Incentive Program. Qualifying homeowners can receive an upfront payment of up to $6,250 through the program.
Homeowners in the Central Hudson, ConEd, NYSEG, National Grid, Orange and Rockland, and Rochester G&amp;E service areas could receive the upfront incentive. Homeowners in the ConEd territory of New York City and Westchester County are eligible for an upfront incentive of $250/kWh, capped at $6,250 per site. For example, customers who install five IQ&#xAE; Battery 5Ps could earn $6,250 upfront. Additionally, homeowners in all other utility territories are eligible for an upfront incentive of $200/kWh, capped at $5,000 per site. Homeowners who install five IQ Battery 5Ps can earn up to $5,000 upfront.

ENPH

Enphase Energy  Announces Homeowners In All Of New York's Major Investor-Owned Electric Utility Service Territories Who Install Enphase IQ Batteries Can Now Qualify To Enroll In The NYSERDA New York Battery Incentive Program

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday.
Shares of Alcon Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) fell sharply in today's pre-market trading as the company posted downbeat results for the first <a href="https://www.benzinga.com/quote/ALC">quarter on Tuesday</a>.
Alcon reported quarterly earnings of 73 cents per share which missed the analyst consensus estimate of 75 cents per share. The company reported quarterly sales of $2.45 billion which missed the analyst consensus estimate of $2.51 billion.
The company lowered its FY2025 earnings guidance, but raised its sales guidance.
Alcon shares dipped 5.5% to $87.79 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) shares dipped 16.7% to $6.11 in pre-market trading after Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) announced plans to sell some of its Aurora Innovation stake in a senior notes offering.</li>
<li>GRAIL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares fell 14.1% to $36.86 in pre-market trading after reporting weak quarterly sales.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) dipped 13.8% to $10.96 in pre-market trading after the company guided first-quarter revenue down and withdrew FY25 guidance.</li>
<li>Allot Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLT#NASDAQ">ALLT</a>) declined 8.1% to $7.79 in pre-market trading after gaining 8% on Tuesday.</li>
<li>XChange TEC.INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XHG#NASDAQ">XHG</a>) dipped 7.5% to $2.33 in pre-market trading after jumping over 12% on Tuesday.</li>
<li>WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) fell 7% to $9.17 in pre-market trading following first-quarter results.</li>
<li>Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) fell 3.2% to $37.77 in pre-market trading.</li>
<li>Pagaya Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGY#NASDAQ">PGY</a>) dipped 3.1% to $14.50 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Movers

ALLT

GRAL

UBER

WBTN

Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Citigroup analyst Andrew Baum downgrades Merck &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) from Buy to Neutral and lowers the price target from $115 to $84.

Citigroup Downgrades Merck & Co to Neutral, Lowers Price Target to $84

Management

GRRR

Gorilla Technology Group Appoints Bruce Bower As CFO

Kala Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALA#NASDAQ">KALA</a>) reported quarterly losses of $(1.41) per share which beat the analyst consensus estimate of $(2.03) by 30.54 percent. This is a 66.43 percent increase over losses of $(4.20) per share from the same period last year.

KALA

Kala Bio Q1 EPS $(1.41) Beats $(2.03) Estimate

Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.18) by 77.78 percent. This is a 28.89 percent increase over losses of $(0.45) per share from the same period last year.

INDP

Indaptus Therapeutics Q1 EPS $(0.32) Misses $(0.18) Estimate

Biotech

General

Incannex Healthcare Completes Patient Dosing In Phase 2 Portion Of Phase 2/3 RePOSA Study Of IHL-42X In Obstructive Sleep Apnea

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies analyst Philippe Houchois downgraded the rating for Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Buy to Hold and maintained the price target of $16. Rivian Automotive shares closed at $14.87 on Tuesday. <a href="https://www.benzinga.com/quote/RIVN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Daina Graybosch downgraded iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Outperform to Market Perform and lowered the price target from $47 to $9. ITeos Therapeutics shares closed at $7.85 on Tuesday. <a href="https://www.benzinga.com/quote/ITOS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Benjamin Theurer downgraded Lavoro Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) from Overweight to Underweight and lowered the price target from $5 to $1.5. Lavoro shares closed at $2.44 on Tuesday. <a href="https://www.benzinga.com/quote/LVRO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Loop Capital analyst Laura Champine downgraded Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) from Hold to Sell and announced a $35 price target. Wayfair shares closed at $39.01 on Tuesday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying W stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080939/image-160-1024x589.png" alt="" class="wp-image-914889" style="width:648px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080939/image-160-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080939/image-160-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080939/image-160-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14080939/image-160.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

ITOS

LVRO

RIVN

This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday

AFCG

UPDATE: Advanced Flower Capital Q1 Adj. EPS $0.21 Misses $0.25 Estimate, Net Interest Income $6.64M Miss $7.61M Estimate

COIN rises over 20 points after Alert from TradePulse
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/13204515/Screenshot-2025-05-13-at-4.38.28%E2%80%AFPM-1010x1024.png" alt="" class="wp-image-12908" /></figure>
CoinBase Global (COIN)&nbsp;today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions.&nbsp;
Today, at&nbsp;10:46 AM on May 13th, a significant trading signal occurred for&nbsp;CoinBase Global Inc., (COIN)&nbsp;as it demonstrated a Power Inflow at a price of&nbsp;$240.74. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Coinbase's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Coinbase's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions.&nbsp;This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for&nbsp;COIN,&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>&nbsp;gives you real-time options trades alerts.&nbsp;
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a>&nbsp;and include firms, like&nbsp;<a href="https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025">https://tradepulse.net/?utm_source=benzinga&amp;utm_medium=article&amp;utm_campaign=brand_awareness_apr2025</a>, which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $240.74. The returns on the High price ($260.42) and Close price ($256.90) after the Power Inflow are respectively 8.2% and 6.7%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

Technicals

Signals

Coinbase Global Rises 8.2% After Key Signal

Events

INAB

IN8bio Presents Preclinical Data From INB-619 Program

Press Releases

ARS Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Conference

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Health Care

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

Comments

ARS Pharmaceuticals

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL